BeOne Medicines (NASDAQ:ONC) Insider Sells $46,973.52 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 132 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $355.86, for a total value of $46,973.52. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Performance

NASDAQ ONC opened at $358.26 on Friday. The stock has a market capitalization of $39.33 billion, a price-to-earnings ratio of 63.07 and a beta of 0.51. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average of $333.94 and a 200 day moving average of $311.69.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.40 by $0.65. The company had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.66 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Sell-side analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 EPS for the current fiscal year.

Institutional Trading of BeOne Medicines

A number of institutional investors have recently made changes to their positions in the company. EFG International AG acquired a new position in BeOne Medicines in the 4th quarter valued at $25,000. Leonteq Securities AG acquired a new stake in BeOne Medicines during the 4th quarter worth $35,000. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines during the 2nd quarter worth $35,000. CWM LLC grew its holdings in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares in the last quarter. Finally, Group One Trading LLC purchased a new stake in shares of BeOne Medicines during the fourth quarter worth $61,000. 48.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ONC has been the subject of several recent analyst reports. TD Cowen boosted their price target on shares of BeOne Medicines from $424.00 to $454.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Truist Financial increased their price objective on shares of BeOne Medicines from $416.00 to $418.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wolfe Research reiterated an “outperform” rating and issued a $370.00 target price on shares of BeOne Medicines in a research report on Monday, August 10th. JPMorgan Chase & Co. boosted their target price on shares of BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, Morgan Stanley restated an “overweight” rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, BeOne Medicines presently has an average rating of “Buy” and a consensus target price of $402.14.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.